Skip to main content

Table 1 Patient disposition in the axitinib and placebo titration arms

From: Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study

Disposition, n (%)

Axitinib Titration n = 56

Placebo Titration n = 56

Discontinued treatment

47 (84)

55 (98)

 Disease progression/relapse

35 (63)

40 (71)

 Adverse event

8 (14)

5 (9)

 Death

2 (4)

1 (2)

 Refusal of treatment for reason other than adverse event

1 (2)

4 (7)

 Global deterioration in health status

1 (2)

1 (2)

 Protocol violation

0

1 (2)

 Other

0

3 (5)

Remaining on treatment

9 (16)

1 (2)